Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 3, 2026

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis
06:48

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis

Published on: May 31, 2020

[MGMT analysis in gliomas].

Véronique Quillien1, Elodie Vauléon, Stephan Saikali

  • 1CRLCC Eugène-Marquis, Rennes, France. v.quillien@rennes.fnclcc.fr

Bulletin Du Cancer
|April 5, 2011
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Proteomic Analysis of Corpora Amylacea Extracted From Post-mortem Brain of MAiD-end-of-life Sporadic ALS Patients.

Brain and behavior·2026
Same author

Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study.

Journal for immunotherapy of cancer·2026
Same author

Case-based reasoning for clinical trial recruitment tools in oncology: When you need patients to find patients.

International journal of medical informatics·2026
Same author

Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.

The Lancet. Oncology·2025
Same author

Selective disruption of DNMT1/ELK1 interactions induces DGKI re-expression and promotes temozolomide sensitivity of MGMT<sup>methylated</sup>/DGKI<sup>methylated</sup> glioblastoma.

Clinical epigenetics·2025

O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a key predictor of glioblastoma treatment response. Determining the optimal MGMT analysis technique is crucial for clinical trials and practice.

Area of Science:

  • Neuro-oncology
  • Molecular diagnostics
  • Cancer genetics

Background:

  • O-6-methylguanine-DNA methyltransferase (MGMT) status predicts response to temozolomide (TMZ) and radiotherapy in glioblastomas.
  • MGMT promoter methylation also serves as an independent prognostic factor in anaplastic gliomas.
  • The DNA repair enzyme MGMT counteracts the effects of alkylating agents like TMZ.

Purpose of the Study:

  • To address the need for optimal MGMT analysis techniques.
  • To evaluate MGMT status determination for clinical trials and practice.

Main Methods:

  • A French multicenter study was established.
  • Focus on determining the best technique for MGMT analysis.

Main Results:

More Related Videos

Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

Related Experiment Videos

Last Updated: Jun 3, 2026

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis
06:48

On-Site Sampling and Extraction of Brain Tumors for Metabolomics and Lipidomics Analysis

Published on: May 31, 2020

Translational Orthotopic Models of Glioblastoma Multiforme
07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

  • MGMT promoter methylation reflects a specific molecular phenotype with prognostic significance.
  • MGMT status is a crucial biological marker in glioma research.

Conclusions:

  • Standardized MGMT analysis is essential for advancing glioblastoma treatment.
  • Further research is needed to optimize MGMT testing methodologies.